Keyword: Cambridge, Massachusetts
InVivo Therapeutics, which specializes in spinal cord injuries, names Richard Toselli, M.D., as its president and chief executive.
Cancer and autoimmune startup Cue Biopharma has ended the year with a potentially lucrative new deal with Merck.
Using tech licensed from Yale University, Inozyme Pharma has emerged from stealth with $49 million and a mission.
Atlas-incubated Kymera Therapeutics has gotten off a $30 million series A and taken on Pierre Fabre’s R&D head as its new chief.